SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry (NYSE: BB) is trending on elevated retail activity ahead of its upcoming fiscal Q2 earnings report, with sentiment turning extremely bullish on expectations for a beat. Traders point to the company's historically conservative guidance as setting up potential upside to revenue, EBITDA, and EPS, echoing analyst commentary that results may come in above estimates and consensus. The QNX story anchors the bull case: the community is highlighting NVIDIA's adoption of QNX 8.0 for automotive and physical AI operating systems, the roughly $950 million QNX royalty backlog, and speculation that a Coretura/Alloy Kore design win would first become visible in backlog rather than near-term results. Bulls argue the safety-software franchise is still mispriced as the old phone business, with some expecting the stock to finally leave single digits around the report. That optimism is meeting pushback from a vocal short contingent calling the run a squeeze setup and urging shorts on every pop, while some longs are taking profits and others are pressing the company over stalled buybacks.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of a potential VK2735 Phase 3 readout is dominating the Viking Therapeutics conversation, with traders split between claims that the obesity data is confirmed and warnings that no press release may come. Bulls frame the stock's slide  roughly a third below its run above $40, per community posts  as a short-squeeze setup given what they describe as heavy short interest, arguing VK2735 can rival Lilly's retatrutide on efficacy and durability; bears counter that a sell-the-news drop to single digits is likely, citing GI tolerability at high doses, limited oral bioavailability, potential weight regain in the maintenance study, and dilution from share sales. A parallel thread is takeover speculation: Novo Nordisk's pipeline setbacks and its statement that its balance sheet could support larger acquisitions have traders debating whether a partnership or a multibillion-dollar buyout of Viking is Novo's most viable path against Lilly, while skeptics doubt big pharma will pay up for assets with tolerability issues. Viking's plan for slower titration in Phase 3 is also being parsed as a tolerability-driven strategy.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares are under sharp selling pressure, and the conversation centers on how the market received the company's Capital Markets Day, where management pointed to mid-single-digit revenue growth in line with peers through 2026, a gradual pricing transition into 2027 as semaglutide faces loss of exclusivity, pipeline diversification, and capacity for larger acquisitions. Reaction is split: many traders say the market 'is not buying it,' faulting leadership ('the market clearly hates the CEO') and overreliance on a single drug, while a bearish Morgan Stanley note adds to the negative tone and some argue investors are selling simply because they see no concrete news to lift the stock. Bulls counter that there is 'no basis for the drop,' citing a single-digit P/E at historically low levels and a strong oral Wegovy launch they view as expanding the obesity market rather than cannibalizing injectables. The announced rebrand to 'Novo' drew heavy mockery, and shares down more than 17% year to date versus Eli Lilly's 6.7% gain keep frustration elevated.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR's volatile price action around crypto regulatory headlines  chiefly the Clarity Act and potential SEC/CFTC rules that could classify tokens like HBAR as commodities  is the dominant topic. Traders repeatedly say the symbol is moving "because of clarity," pointing to a procedural vote to begin debate on the bill and arguing over which party is stalling it, while others suspect a government news-driven pump designed to be sold into. The community is split: bulls say it is not the time to sell ahead of potential commodity classification and cite Hedera's enterprise positioning, new Council partners such as SpaceDev, growing MainNet accounts, and expanding tokenized-asset activity. Bears short the rallies, call the move market manipulation, note HBAR struggling below resistance near $0.08 with the 200-day MA near $0.068 in focus, and a smaller group attributes the pullback to Grayscale pulling its HBAR ETF filing.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as traders react to sharp, headline-driven swings in oil tied to the Iran conflict and the Strait of Hormuz. Reports that Iran offered to reopen the strait within seven days and sent ceasefire terms to Washington through Qatar coincided with steep drops in the fund, with many traders noting USO tanks whenever escalation slows  even as WTI holds in the mid-$90s to low-$100s. The community is split: bears argue the war premium is fading, citing demand destruction, inventory builds, and large potential supply from Greenland and Venezuela, and are pressing short setups; bulls counter that supply is genuinely tight, pointing to record diesel prices in Europe, jet fuel shortages, refinery maintenance, and slowed US drilling, and view dips as buying opportunities. A recurring complaint is that USO seems to lag or decouple from spot crude, fueling accusations of manipulation among bears and frustration among bulls who see no reason for the ETF to be down amid bearish supply headlines. Some traders also link oil's fade from roughly $107 toward $100 to the broader equity rally and rate-hike pressure, making crude the dominant factor for overall market direction.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne's latest quarterly earnings report is driving the conversation: results came in above guidance and consensus on key metrics, with Q3 revenue guided above estimates and full-year outlook raised, yet the stock sold off sharply  described by community members as the only major cybersecurity name in the red while CrowdStrike's strong results lifted the sector. Traders are split on the reaction: many call the roughly 5% drop an overreaction to a beat-and-raise, while others cite what they see as lackluster guidance quality, only 13 net new $100K+ customer additions, and speculation ranging from insider selling to an analyst downgrade as explanations for the selling.

A valuation debate dominates the discussion: bulls repeatedly contrast SentinelOne's ~7x price-to-sales and ~$7B market cap against CrowdStrike's ~40x and Palo Alto Networks' ~25x, arguing the stock merits a re-rating if the market accepts peers' multiples amid a broader AI-cybersecurity rally. Takeover speculation also recurs  long-circulating rumors of Palo Alto Networks as a potential acquirer, alongside the company's zero-debt balance sheet, $1B+ in cash, and an estimated $500M equity stake in Anthropic cited as potential appeal to big-tech buyers. Short sellers were active around the confirmed breakout levels bulls had been trading.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is drawing attention on a steady stream of AI business announcements layered over a sharp technical move on expanding volume. Traders are focused on a run of signed enterprise AI services contracts  token-based agreements, an RMB1.65 million deal the company says was delivered, accepted, and paid in full, an RMB7.68 million agreement, and an RMB10 million-plus Zhongchuang Liankong contract targeted for Q3 delivery  along with its Lingyan Miaoyu LLM, a consumer access portal, and an AI security white paper. Bulls argue the string of small but confirmed contracts, plus subsidiary Huazhi Future's energy-infrastructure and robotics work, signals a genuine platform building across compute, models, and industry deployments, with some citing a strong balance sheet and growing ARR. Skeptics counter by asking why the stock fell on positive news and want volume and short-interest confirmation before chasing a violent small-cap move. Other traders frame the activity as a catalyst-scanner-momentum feedback loop in a low-float name that has outperformed the broader Hong Kong tech tape.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is trending on a sharp single-session surge that added roughly $200 billion in market value  its biggest one-day gain in over a year  after reports that its Muse AI agent topped U.S. iPhone and Android download charts. Muse has become the dominant talking point, with the market repricing what the app 'might become' rather than its current revenue contribution.

The community is sharply split. Bulls argue Muse is more user-friendly than ChatGPT and see the app as evidence Meta's heavy AI spending can drive real user growth and pressure OpenAI and Anthropic, with some speculating about a run toward a $2 trillion market cap and others crediting Meta with single-handedly lifting the broader tech complex. Skeptics counter that the move is disconnected from fundamentals  the app is free with no clear profit model  and many attribute the spike to gamma-squeeze, short-squeeze, or algo-driven flows rather than news, with several traders actively short or calling for a 'sell the news' fade. Privacy concerns over Meta's handling of personal data and doubts that Muse outperforms Claude or ChatGPT reinforce the bear case. Amazon's reported decision to block Muse from its retail site as an unauthorized AI agent is adding a second layer to the debate, with some users refusing to adopt the agent without Amazon access and others reading the block as a signal of how platforms view agentic AI.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Trader attention on IREN is centered on the stock's repeated failure to advance alongside a sharp Nasdaq rally. A large contingent of bulls alleges market manipulation and points to what they describe as elevated short interest across neocloud and AI data-center names  including claims that roughly a quarter of the float is short  as the reason gains keep getting sold, fueling short-squeeze expectations. Other traders are shorting the stock outright, calling rallies an easy fade. The bull narrative leans on IREN's transition from Bitcoin mining to AI/HPC data centers, partnerships with Nvidia and Microsoft, and a Northland analyst initiation, with much of the debate focused on whether the stock can clear and hold the $50 level.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD's run to the $1 trillion market cap milestone is dominating the conversation, with traders celebrating the stock as the newest trillion-dollar chip name alongside Nvidia and Broadcom after a steep rally that traders noted added roughly $300 billion in market value and has lifted shares more than 175% year-to-date. The reaction is a tug-of-war between euphoria and disbelief: retail sentiment readings turned extremely bullish, short sellers were mocked as 'wrecked,' and many warned against betting against the move amid FOMO and short-squeeze dynamics, while some shorts persisted  one arguing that companies historically give back about 15% within weeks of crossing $1 trillion. Skeptics called the rally speculative and stretched, pointing to a $600-plus share price against roughly $2.65 of EPS, valuation they viewed as far richer per dollar than other chip megacaps, and questioning how the stock keeps climbing without a sell-off; others debated locking in profits. Context includes AMD's positioning as the No. 2 AI chip supplier to Nvidia, chip-demand optimism tied to Meta's Muse AI, and its OpenAI partnership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OmniAb to Host Investor & Analyst Day on October 6, 2026

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from...

OmniAb to Participate in Upcoming Investor Conferences

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced managements participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026...

The Nasdaq Stories Traders Can't Ignore

Here are today’s catalysts that are changing the narrative. $NTHI, $IPST, $OABI, $LLY, $HIVE, and $IVF

Why Is Omniab Stock Rallying After Eli Lilly Deal?

The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarketread more...

OmniAb Lands Lilly and Raises Guidance: $370M Deal Puts OABI’s Discovery Platform in the Spotlight

OmniAb (NASDAQ:OABI) may be one of the more interesting picks-and-shovels stories emerging in biotech, and its latest deal with Eli Lilly & Company (NYSE:LLY) could be another indication that the pharmaceutical industry sees value in the company’s technology rather than simply another early-stage drug program.

OmniAb Raises 2026 Financial Guidance

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. Recent business development and licensing...

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages...

OmniAb (OABI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +54.55% and +149.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026...

OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

OmniAb Inc

Bearish Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.13	--	--	N/A
Q2 '26	-$0.12	-$0.05	58.33%	BEAT
Q1 '26	-$0.10	-$0.06	42.47%	BEAT
Q4 '25	-$0.09	-$0.11	-25.04%	MISSED
Q3 '25	-$0.14	-$0.14	--	EXPECTED

Feed

News

Sentiment

Earnings

Fundamentals

Info

OABI Earnings

Upcoming Earnings: Q3 '26

Historical Earnings